Hannelius

A new analysis that supports the effect of the diabetes vaccine Diamyd® will be presented at a scientific conference on 13 October

Retrieved on: 
Thursday, September 23, 2021
ISPAD, Clinical trial, Diamyd Medical, International Society for Pediatric and Adolescent Diabetes, Hyperglycemia, GAD65, Society, Hannelius, ASHG, Diabetes, Patient, Type 1, Glycated hemoglobin, Eli Lilly and Company, Pediatrics, Continuous glucose monitor, International Society of Sculptors, Painters and Gravers, CEO, Blood, Meta-analysis, Company, Adolescence, Congress, Uppsala University Hospital, Human genetics, CGM, Hypoglycemia, Insulin, IIB, HLA, Nasdaq, EASD, Regeneration, Pharmaceutical industry

The analysis is based on data from Continuous Glucose Montitoring (CGM) and will be presented by Professor Johnny Ludvigsson, Principal Investigator of the clinical trial DIAGNODE-2.

Key Points: 
  • The analysis is based on data from Continuous Glucose Montitoring (CGM) and will be presented by Professor Johnny Ludvigsson, Principal Investigator of the clinical trial DIAGNODE-2.
  • Complete results will be submitted for publication in a scientific journal later this year.
  • The diabetes vaccine Diamyd is an antigen-specific immunotherapy for the preservation of endogenous insulin production.
  • A vaccine manufacturing facility is being set up in Ume for the manufacture of recombinant GAD65, the active ingredient in the therapeutic diabetes vaccine Diamyd.

A new analysis that supports the effect of the diabetes vaccine Diamyd® will be presented at a scientific conference on 13 October

Retrieved on: 
Thursday, September 23, 2021
ISPAD, Clinical trial, Diamyd Medical, International Society for Pediatric and Adolescent Diabetes, Hyperglycemia, GAD65, Society, Hannelius, ASHG, Diabetes, Patient, Type 1, Glycated hemoglobin, Eli Lilly and Company, Pediatrics, Continuous glucose monitor, International Society of Sculptors, Painters and Gravers, CEO, Blood, Meta-analysis, Company, Adolescence, Congress, Uppsala University Hospital, Human genetics, CGM, Hypoglycemia, Insulin, IIB, HLA, Nasdaq, EASD, Regeneration, Pharmaceutical industry

The analysis is based on data from Continuous Glucose Montitoring (CGM) and will be presented by Professor Johnny Ludvigsson, Principal Investigator of the clinical trial DIAGNODE-2.

Key Points: 
  • The analysis is based on data from Continuous Glucose Montitoring (CGM) and will be presented by Professor Johnny Ludvigsson, Principal Investigator of the clinical trial DIAGNODE-2.
  • Complete results will be submitted for publication in a scientific journal later this year.
  • The diabetes vaccine Diamyd is an antigen-specific immunotherapy for the preservation of endogenous insulin production.
  • A vaccine manufacturing facility is being set up in Ume for the manufacture of recombinant GAD65, the active ingredient in the therapeutic diabetes vaccine Diamyd.